http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
김제학(Je Hak Kim),김현수(Hyun Su Kim),김영훈(Young Hoon Kim),정성목(Seong Mok Jeong),신재규(Jae Kyu Shin),최재묵(Jae Mook Choi),고형곤(Hyung Kon Ko) 한국응용약물학회 1997 Biomolecules & Therapeutics(구 응용약물학회지) Vol.5 No.3
CJ-50001 is a recombinant granulocyte-colony stimulating factor (rG-CSF) synthesized by recombinant DNA technology using E. coli as an expression system. The general pharmacological properties of CJ50001 were evaluated in mice, rats, dogs and isolated guinea pig ileum. The doses are 100, 300 and 1,000 ㎍/㎏, i.v. for mice and rats, 1, 10 and 100 ㎍/㎏, i.v. for dogs and 1 and 10㎍/ml for isolated guinea pig ileum. Intravenous administration of CJ-50001 at this dose range did not affect general behavior, central nervous system, smooth muscles, gastrointestinal system, cardiovascular and respiratory system and water and electrolytes excretion. In summary, CJ-50001 had no harmful pharmacological effect in these studies even up to the 200-fold expected clinical dose, 250 ㎍/man.
마우스에서 항암제 유발 호중구감소에 대한 CJ-50001 의 회복촉진효과
김제학(Je Hak Kim),김현수(Hyun Su Kim),백남진(Nam Jin Baek),김달현(Dal Hyun Kim),최재묵(Jae Mook Choi),강재구(Jae Ku Kang),김기완(Ki Wan Kim) 한국응용약물학회 1997 Biomolecules & Therapeutics(구 응용약물학회지) Vol.5 No.4
Neutropenia is a major dose-limiting side effect of cancer chemotherapy. The therapeutic effects of CJ-50001 were examined on neutropenia caused by anticancer agents. Neutropenia was induced by cyclophosphomide (130 mg/kg), doxorubicin (4.5 mg/kg), and vincristine (1 mg/kg) in normal ICR mice and by cyclophosphamide (200 mg/kg) in CT26 adenocarcinoma bearing BALB/C mice. After the subcutaneous injection of anticancer agents, we administered subcutaneously recombinant human granulocyte-colonystimulating factor (100 ㎍/kg/day) to mice in order to stimulate neutrophil production. In normal and tumor-bearing mice, neutrophil production efficacy of CJ-50001 (rG-CSF) was similar to that of Grasin. These results suggest that CJ-50001 could be effective in its clinical use for neutropenia treatment.
유전자 재조합 B 형 간염 바이러스 표면 항원 , CJC-50100 의 일반약리작용
정성학(Seong Hak Jeong),최재묵(Jae Mook Choi),이남중(Nam Jung Lee),전형수(Hyung Soo Jeon),김연희(Yon Hee Kim),김재승(Jae Seung Kim),하석훈(Suk Hoon Ha),김영훈(Young Hoon Kim),이나경(Na Gyung Lee),김제학(Je Hak Kim),박완제(Wan Je Park 한국응용약물학회 2001 Biomolecules & Therapeutics(구 응용약물학회지) Vol.9 No.1
N/A CJC-50100 is a recombinant hepatitis B virus surface antigen (HBsAg) expressed in yeast. The general pharmacological properties of CJC-50100 were evaluated in mice, rats, dogs and isolated guinea pig ileum. The doses were 0.33∼33.3 ㎍/㎏ i.m. for mice and rats and 3.3∼9.9 ㎍/㎏ i.v. for dogs. The concentrations of 0.002∼0.02 ㎍/mlwere used for the assay with guinea pig ileum. Intramuscular administration of CJC-50100 at the doses did not alter general behavior and the responses for central nervous system, smooth muscle, gastrointestinal system, cardiovascular and respiratory system, and water and electrolytes excretion. In summary, CJC-50100 had no pharmacological effect in these studies even up to the 100-fold of the expected clinical dose, 20 ㎍/man/60 kg.
안지오텐신 2 수용체 길항약 CJ-10513 이 고빈도 심실 pacing 견에서의 혈행동태에 미치는 영향
김영훈(Young Hoon Kim),정성목(Seong Mok Jeong),신재규(Jae Kyu Shin),최재묵(Jae Mook Choi),정성학(Seong Hak Jeong),배훈(Hoon Bae),이건호(Gun Ho Lee),김제학(Je Hak Kim),안양수(Yang Soo An) 한국응용약물학회 1998 Biomolecules & Therapeutics(구 응용약물학회지) Vol.6 No.2
Acute hemodynamic effects of CJ-10513, a non-peptide angiotensin II receptor antagonist, were examined in mongrel dogs treated with high frequency ventricular pacing for one week. Rapid ventricular pacing reduced mean blood pressure (mBP), LVdP/dt and cardiac output (CO), and increased the left ventricular end-diastolic pressure (LVEDP) and pulmonary capillary wedge pressure (PCWP). Continuous infusion of CJ-10513 at doses of 10 and 20 ㎍/kg/min, respectively, for 30 minutes reduced mBP, LVEDP and myocardial oxygen consumption rate (MVO₂) and shifted the cardiac function curve (CO-LVEDP curve) to the left in this dog model. In conclusion, CJ-10513 decreased the preload and afterload and increased the cardiac function in dogs with pacing-induced heart failure.
섬수 ( Bufonis Venenum ) 추출물의 약리작용
김영춘(Young Hoon Kim),정성학(Seong Hak Jeong),김종호(Jong Ho Kim),최재묵(Jae Mook Choi),지준환(Joon Hwan Ji),강재구(Jae Koo Kang),박종구(Jong Koo Park),김제학(Je Hak Kim),조희재(Hi Jae Cho) 한국응용약물학회 2001 Biomolecules & Therapeutics(구 응용약물학회지) Vol.9 No.1
N/A Bufonis Venenum is a toad venom and its main components are bufadienolides, namely resibufogenin, bufalin and cinobufagin. The desensitizing effect of Bufonis Venenum is useful for the treatment of the premature ejaculation in Chinese medicine. But, minor components of Bufonis Venenum cause problems such as topical burning, pain, and erectile dysfunction. To clarify and eliminate the components responsible for these side effects, we prepared two extracts of Bufonis Venenum with either 70% ethanol or ethylacetate and tested their pharmacological effects. The extract of Bufonis Venenum with 70% ethanol produced pain response in rat hind paw, and exhibited contraction of rabbit corpus cavernosal muscle in vitro. On the other hand, the ethylacetate extract did not cause pain and smooth muscle contraction. The desensitizing effect of the ethylacetate extract was similar to that of the 70% ethanol extract. In conclusion, these results show that the extract of Bufonis Venenum with ethylacetate does not have the components causing side effects and deserve further study for therapeutic potential in premature ejaculation in men.
골수염 치료제인 항생제비드 ( CJ-40003 ) 유효성분의 일반약리작용
김영훈(Young Hoon Kim),최재묵(Jae Mook Choi),온윤성(Yoon Seong On),연규정(Kyu Jeong Yeon),이윤하(Youn Ha Lee),김제학(Je Hak Kim),이영수(Young Soo Lee) 한국응용약물학회 1999 Biomolecules & Therapeutics(구 응용약물학회지) Vol.7 No.1
A new antibiotic bead, CJ-40003 is a combination of three antibiotics, tobramycin, vancomycin and cefazolin embedded in bone cement, for the treatment of osteomyelitis. To evaluate the general pharmacological properties of CJ-40003, the effects of its active ingredients were investigated in mice, rats, dogs and isolated guinea pig ileum. The combination of three antibiotics (CA) did not affect general behavior, central nervous system, smooth muscles, gastrointestinal system, cardiovascular and respiratory system and water and electrolytes excretion when administered intravenously at the doses of 0.3, 1 and 3 mg/kg, respectively, into experimental animals. The CA had no effect on the contractile response of the isolated guinea pig ileum to various spasmogen at concentrations of 1, 3 and 10 ㎍/ml, respectively. In conclusion, the active ingredients of CJ-40003 showed no pharmacological effect in these studies.
백남진,강재구,김달현,목헌,김제학,김현수,Baek, Nam-Jin,Kang, Jae-Ku,Kim, Dal-Hyun,Mok, K.-Hun,Kim, Je-Hak,Kim, Hyun-Su 한국독성학회 1997 Toxicological Research Vol.13 No.3
Antigenic potential of genetically engineered human granulocyte colony-stimulating factor (CJ-50001) was assessed in guinea pigs and mice. In active systemic anaphylaxis (ASA) test, although CJ-50001 at 50 $\mu\textrm{g}$ /head induced anaphylactic responses, CJ-50001 5 $\mu\textrm{g}$ /head alone or 50 $\mu\textrm{g}$ / head with adjuvant did not induce anaphylactic responses. In passive systemic anaphylaxis test (PCA) or passive hemagglutination test (PHA), CJ-50001 did not induce positive responses. It is concluded that, in light of the fact that CJ-50001 was antigenic only in ASA but not in PCA or PHA and also that CJ-50001 is a foreign human recombinant protein to guinea pigs, CJ-50001 may not induce systemic allergic react-ion in its clinical use in human.
CJ-50001 (recombinant human granulocyte-colony stimulating factor) 의 흰주와 개에서의 약물동태학적 연구
김성남(Sung Nam Kim),신재규(Jae Kyu Shin),이수정(Soo Jung Lee),정용환(Yong Hwan Jung),하석훈(Suk Hoon Ha),김기완(Ki Wan Kim),고형곤(Hyung Kon Koh),김제학(Je Hak Kim) 한국응용약물학회 1998 Biomolecules & Therapeutics(구 응용약물학회지) Vol.6 No.4
The pharmacokinetics of CJ-50001 (recombinant human granulocyte-colony stimulating factor, developed by R&D center of Cheil Jedang Corp.) were investigated in rats and dogs. The serum concentrations of CJ-50001 were measured by a sandwich enzyme immunoassay. After single intravenous (iv) administration of CJ-50001 to rats at a dose of 5 ㎍/kg, the mean terminal half-life and area under the concentration-time curve (AUC) were 0.96 h and 124.49 ㎍·/ml, respectively. After single subcutaneous (sc) administration at the same dose, maximum serum concentration was observed at about 2 hours after administration, and the mean terminal half-life, AUC and the bioavailability were 1.11 h, 63.58 ㎍·h/ml and 51.07%, respectively. In repeated dosing studies, CJ-50001 was administered iv and sc to rats at a daily dose of 5 ㎍/kg for 7 days. The pharmacokinetic parameters, such as mean AUC and terminal half-life, were not significantly different from those of single administration. Following single iv and sc administration of CJ50001 to dogs at a dose of 5 ㎍/kg, mean AUCs were much higher than those of rats, due to the decreased clearence (CL). After sc administration to dogs, maximum serum concentration was observed at 2∼4 hours after administration and the bioavailability was 54.60%.